BRD4 and hematologic disorder: Preclinical and clinical studies have demonstrated the efficacy of BET inhibition in several hematological malignancies 29, 30, in which inhibition of BRD4 leads to downregulation of MYC expression 31, a master regulator of cell survival and proliferation 32.